Trump administration weighs temporary sales of some unapproved peptides
The Washington Post reports the White House is moving toward a carve-out, though no signed order, legal basis or product scope has been disclosed.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 7 21:08 ETSource: Newsquawk
The wire
- 01Newsquawk relayed a Washington Post report that the Trump administration is moving toward allowing temporary sales of certain unapproved peptides.
- 02Any such pathway would bear directly on compounders, telehealth sellers and clinicians now operating around FDA's 503A bulk substances categories.
- 03The item is sourced to a single newspaper report of direction, not a rule; watch for a formal agency notice with an effective date and defined product list.
From the source
Read at newsquawk.comUS President Trump administration moves towards temporary sales of some unapproved peptides, according to Washington Post
Every headline is on the live feed 20 minutes before this site.
